Literature DB >> 21328429

Imatinib as the first-line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: can we compare real life data to the results from clinical trials?

Daniela Zackova1, Hana Klamova, Ladislav Dusek, Jan Muzik, Katerina Machova Polakova, Jana Moravcova, Tomas Jurcek, Dana Dvorakova, Zdenek Racil, Zdenek Pospisil, Alexandra Oltova, Kyra Michalova, Jana Brezinova, Filip Razga, Michael Doubek, Petr Cetkovsky, Marek Trneny, Jiri Mayer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21328429     DOI： 10.1002/ajh.21942

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  6 in total

Review 1.  How I treat newly diagnosed chronic phase CML.

Authors:  Jorge Cortes; Hagop Kantarjian
Journal:  Blood       Date:  2012-05-21       Impact factor: 22.113

2.  Similar outcome of patients with chronic myeloid leukemia treated with imatinib in or out of clinical trials.

Authors:  Musa Yilmaz; Hagop Kantarjian; Elias Jabbour; Susan O'Brien; Gautam Borthakur; Srdan Verstovsek; Guillermo Garcia-Manero; Farhad Ravandi; Jan Burger; Sherry Pierce; Alfonso Quintas-Cardama; Jorge Cortes
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-09-20

3.  Estimation of current cumulative incidence of leukaemia-free patients and current leukaemia-free survival in chronic myeloid leukaemia in the era of modern pharmacotherapy.

Authors:  Tomáš Pavlík; Eva Janoušová; Zdeněk Pospíšil; Jan Mužík; Daniela Záčková; Zdeněk Ráčil; Hana Klamová; Petr Cetkovský; Marek Trněný; Jiří Mayer; Ladislav Dušek
Journal:  BMC Med Res Methodol       Date:  2011-10-11       Impact factor: 4.615

4.  Real life patterns of care and progression free survival in metastatic renal cell carcinoma patients: retrospective analysis of cross-sectional data.

Authors:  Rana Maroun; Laura Mitrofan; Laure Benjamin; Gaelle Nachbaur; Franck Maunoury; Philippe Le Jeunne; Isabelle Durand-Zaleski
Journal:  BMC Cancer       Date:  2018-02-21       Impact factor: 4.430

5.  Evaluation of 5-year imatinib treatment of 458 patients with CP-CML in routine clinical practice and prognostic impact of different BCR-ABL cutoff levels.

Authors:  Hana Klamová; Kateřina Machová Poláková; Jan Mužík; Zdeněk Ráčil; Daniela Záčková; Kateřina Steinerová; Michal Karas; Edgar Faber; Eva Demečková; Zuzana Michalovičová-Sninská; Jaroslava Voglová; Ludmila Demitrovičová; Eva Mikušková; Elena Tóthová; Juraj Chudej; Imrich Markuljak; Eduard Cmunt; Jana Moravcová; Dana Dvořáková; Kyra Michalová; Marie Jarošová; Markéta Marková Sťastná; Petr Cetkovský; Ladislav Dušek; Vladimír Koza; Marek Trněný; Karel Indrák
Journal:  Cancer Med       Date:  2013-02-21       Impact factor: 4.452

6.  Determinants of survival in patients with chronic myeloid leukaemia treated in the new era of oral therapy: findings from a UK population-based patient cohort.

Authors:  A G Smith; D Painter; D A Howell; P Evans; G Smith; R Patmore; A Jack; E Roman
Journal:  BMJ Open       Date:  2014-01-15       Impact factor: 2.692
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.